Ghana’s pharmaceutical market is entering a pivotal phase. As demand for quality-assured medicines rises, so does demand for greater local and regional production. Upholding current Good Manufacturing Practices (cGMP) is central to this growth.
Increasing cGMP compliance and meeting international quality standards can help pharmaceutical companies access new market opportunities, attract investment, and scale business.
This playbook is a tool for chief executive officers (CEOs), chief operating officers (COOs), and business leaders making critical strategic investment decisions. The playbook provides:
- A business-oriented roadmap for achieving and sustaining cGMP compliance
- Guidance on sequencing investments in people, systems, and facilities
- A structured framework for choosing between retrofit, brownfield, and greenfield facility strategies
- Practical insights from comparable African manufacturers
The question facing Ghanaian manufacturers is no longer whether to invest in cGMP, but how and when. Early movers can help shape future markets; late adopters risk being left behind.
Specifically, cGMP upgrades, when aligned with a viable product and market strategy, expands access to larger, more diverse buyers; reduces internal failures; improves production efficiency; and limits regulatory disruption.
